Ren Mao,MD,PhD (@IBD_Sir) profile picture

An IBD reseacher seeking truth,a doctor seeking hope. Gastroenterologist with focus on #IBD, especially intestinal stricture.

Cleveland Heights, OH
Joined August 2019
Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)Photo by Ren Mao,MD,PhD (@IBD_Sir)
Ren Mao,MD,PhD retweeted
❤️ honoured to meet you and share thoughts with Prof Sung-Ae , Prof Byong & Prof Ren Korean #IBD is in great hands 👏 with the amount of high quality work going on . Look forward to future collaborations
2
6
282
Good to see you!! 😄 @Dr_BDYE @IBD_Sir #SungAeJung
#IBD has no borders Keen to hear and see first hand the progress in #IBD care and research in east asia particularly South Korea Attending #KDDW in Seoul Looking forward to connecting with #IBD colleagues in the region @BDYE_IBD @sang_hyoung @sunnyheiwong @TakuKobayashiM1
1
2
18
742
Ren Mao,MD,PhD retweeted
🎤 Spoke on emerging endoscopic interventions at #AIDDS2026, Asan, Seoul. A focused, high-level IBD meeting spanning AI, dysplasia, fibrosis, creeping fat and interventional endoscopy—with stimulating discussions across disciplines! 🇰🇷 Grateful to Asan IBD’s Prof @BDYE_IBD , Prof @sang_hyoung , Prof Dong-Hoon Yang & Prof Sung Wook Hwang for the warm hospitality, and to @IBD_Sir , Prof Yasuharu Maeda & fellow Korean speakers for the excellent scientific exchanges! 🙏 #AIDDS2026 #IBD
4
21
897
Ren Mao,MD,PhD retweeted
Just wrapped up an excellent presentation on PALI-2108! Once-daily gut-targeted PDE4 inhibition is showing early improvements in fibrostenotic Crohn's. Exciting Phase 1b data for a tough-to-treat phenotype! #IBD #UEGWeek @my_ueg
18
3
44
2,370
Ren Mao,MD,PhD retweeted
Three long-acting antibodies. One at a time. That was SKYLINE Part A, presented by Silvio Danese at UEG Week this afternoon. Spyre's SPY001 (α4β7), SPY002 (TL1A) and SPY003 (IL-23) are engineered to last, with half-lives of 75 to 85 days. The plan is subcutaneous maintenance every three to six months. Open-label. Week 12. About 45 patients per arm. Clinical remission 40%, 33% and 20%. Histology (primary endpoint) improved by around 60% in every arm. No drug-related serious adverse events. The headline numbers were already out (press release). Today they sat side by side, and that is where it gets interesting. My read. Each one works. SPY001 looks strongest, but 81% of its patients were treatment-naive. SPY002 sits where the TL1A class sits. SPY003 came in below where IL-23 drugs usually land in similar patients. And there is no placebo ... which is also good. But open-label numbers flatter. The real test is Part B. Placebo-controlled, three combinations, readout in 2027. J&J's DUET-UC has already shown how hard it is for two drugs to clearly beat one. Single targets got us here. Combinations have to earn their place. @my_ueg @spyretx @silvio_silvio75
1
14
31
2,950
Ren Mao,MD,PhD retweeted
Time to reflect and celebrate #VERDICT With those who were instrumental in conceiving (@PeyrinBiroulet ) and delivering (@vipuljairath ) Fitting tribute to #ProfFeagan Thanks to all the patients who participated in this practice changing study
2
5
1
47
3,008
Ren Mao,MD,PhD retweeted
One of a kind anti-fibrotic, Ontunisertib. Results from OLE presented by @IBD_FloMD. ➡️ Well tolerated, no safety concerns ➡️No stricture progression on MRE ➡️3% EBD/✂️; only 1 EBD/48 weeks @AnjaMD_IBD @JordiRimola @RPanaccione @BettenworthDb #STARconsortium #UEGWeek @my_ueg
17
1
27
1,238
Ren Mao,MD,PhD retweeted
Thank you @KR_Foundation for including me. This is an inspiring conference. We are grateful for you supporting the #IBD community. @ManuelBragaMD @JosephHabibi_MD @HolubarStefan @AnthonydeBuck
Dr. Florian Rieder @IBD_FloMD of the Florian Rieder Laboratory at @CCLRI, is presenting on cracking the nut of stricturing Crohn’s disease. #InnovationsSymposium2026 Explore his research into new ways to treat IBD patients with established strictures: lerner.ccf.org/inflammation-…
1
7
19
1,655
Ren Mao,MD,PhD retweeted
1/When we diagnose IBD, we don't know which therapy will work for that patient. Could the biopsies we already take give us clues?
Presenting a valuable intestinal cell atlas: doi.org/10.1172/JCI202488 @MikeKattahMD, @alexis_combes & team @UCSFMedicine applied spatial gene mapping to archived colitis biopsies, identifying immune cell neighborhoods that explain why some patients are resistant to vedolizumab and others respond well. @MayoClinic #Colitis #IBD
2
20
54
8,296
Ren Mao,MD,PhD retweeted
🚨Hot off the press: updated #ECCO GL on medical and surgical treatment of #ulcerativecolitis The update addresses new therapies, rescue strategies, treat-to-target care and the evolving role of surgery @Y_ECCO_IBD @IBD_FloMD @DignassAxel @RajaAtreya
13
32
2,857
Ren Mao,MD,PhD retweeted
We are delighted today to hear Dr Florian Rieder discuss stricturing Crohn’s disease! @IBD_FloMD @MayoClinicGIHep @clevelandclinic flagellin stimulates fibroblasts
1
17
44
2,902
Ren Mao,MD,PhD retweeted
📣 New episode out for #IBDEssentials: @RPanaccione discusses recent clinical trial results informing clinical decision making youtu.be/NE0BYpuMI60?si=steX… via @YouTube - check it out… @CathyLuMD @DignassAxel @DCharabaty
1
1
1
14
2,002
Ren Mao,MD,PhD retweeted
🔬#STARConsortium Industry Meeting at #DDW2026🔬29 corporate partners, investors, regulatory experts and interdisciplinary clinical scientists all in for one mission: Building a pathway to testing anti-stricture therapies in Crohn’s disease. #SmallEgoBigResults @MRegueiroMD
2
12
1
34
2,899
Welcome back to Guangzhou ASAP, 😄
Just wrapped up an incredible #DDW2026! Thrilled to have shared our team's latest research on the premier stage for gastroenterology. A massive year for us: 1 Late-Breaking Abstract + 3 Oral Presentations! 🎉 Excited to share the highlights 👇
2
176
Ren Mao,MD,PhD retweeted
1
5
14
842
Great Rirong
Childhood Exposure to Sibling with CD associated with Increased risk of CD and Altered Microbial Signatures @DDWMeeting @RirongChen @TurpinWilliams @KenCroitoru @The_GEMProject @SinaiHealth @guthealthmd @annegri50789035
1
1
144
amazing steps
Fibrostenotic #Crohns disease is entering a new phase of clinical development🔬 At the #STAR Consortium Industry Meeting during #DDW it was inspiring to see progress in PRO tools, biomarkers, trial frameworks, and potential anti-fibrotic therapies #FlorianRieder #IBD
1
1
4
247